SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT01019655

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Low Molecular Weight Heparin for Pregnant Women With Thrombophilia: a Prospective, Randomized, Open Trial

The purpose of this study is to investigate whether heparin is an effective treatment in pregnant women at risk for thrombosis and other pregnancy-associated complications.

NCT01019655 Pregnancy and Thrombophilia
MeSH: Thrombophilia
HPO: Hypercoagulability

1 Interventions

Name: Nadroparin calcium

Description: nadroparin calcium (fraxiparin®) 0.3 mL daily during pregnancy and six weeks post partum

Type: Drug

Nadroparin calcium


Primary Outcomes

Measure: composite endpoint: pregnancy-associated thrombosis/thromboembolism, miscarriage, preeclampsia, intrauterine growth retardation

Time: 10.5 months

Purpose: Prevention

Allocation: Randomized

Parallel Assignment


There is one SNP

SNPs


1 G20210A

Inclusion Criteria: - Pregnant women with a singleton pregnancy - Age >18 years - Ability to understand informed consent form Exclusion Criteria: - Allergy/hypersensitivity for nadroparin calcium - Heparin-associated thrombocytopenia - Organ lesions at risk for bleeding such as acute stomach/bowel ulcers, cerebral hemorrhage, cerebral aneurysm - uncontrolled hypertension - Liver and/or renal dysfunction - Known hematologic disease Inclusion Criteria: - Pregnant women with a singleton pregnancy - Age >18 years - Ability to understand informed consent form Exclusion Criteria: - Allergy/hypersensitivity for nadroparin calcium - Heparin-associated thrombocytopenia - Organ lesions at risk for bleeding such as acute stomach/bowel ulcers, cerebral hemorrhage, cerebral aneurysm - uncontrolled hypertension - Liver and/or renal dysfunction - Known hematologic disease Pregnancy and Thrombophilia Thrombophilia Women with thrombophilia, i.e. carriage of a factor V leiden mutation, a factor II prothrombin G20210A mutation or a reduced amount of antithrombin III, protein C or protein S, are at elevated risk for thrombosis and related sequelae. --- G20210A ---



HPO Nodes


HPO:
Hypercoagulability
Genes 17
GATA2 AGGF1 MYD88 F5 HRG DLD F9 PLAT THBD SPTA1 EPB42 SPTB PROC SLC4A1 PROS1 PIGA ANK1